




# ERNs and Research: state of play from the European Commission perspective

#### **`Snapshot'** ERNs and Medicinal Product Point of View


Anneli Torronen, DG SANTE European Commission

### Pharmaceutical System in the EU: Marketing Authorisation (MA) and monitoring of the medicinal products

- ERNs and the whole life cycle of the Medicinal Product



#### Pharmaceutical legislation in the EU



#### **ERNs and the special interests**

Orphan Regulation (EC) No 141/2000	Paediatrics Regulation (EC) No 1901/2006	Advanced therapy products (ATMP) Regulation (EC) No 1394/2007
Rare disease (not more	Ensure high-quality	The medical products based
than 5 in 10,000 persons	research into	on gene therapy, cell therapy
in the EU) or not	developments of	and tissue engineering
sufficient return on	medicines for children	Considerable research
investment	Ensure that over time	activities, with several
Seriousness: life-	majority of medicines	hundred registered clinical
threatening or chronically	used for children are	trials on ATMPs in the EU
debilitating	authorised for such use	over the last ten years
No satisfactory method of	Ensure availability of	Demonstrates that research
treatment or if existing	high-quality information	in ATMPs is significant; the
significant benefit has to	about medicines used by	majority is carried out by
be demonstrated	children	SMEs, hospitals or academia




## **Recent up- date ATMPs**

- Supporting the development of ATMPs through an optimised application of current legal framework
- EC-EMA joint action plan on ATMPs (2017-2019)
- Specific GMP framework adopted
- GCP for ATMPs in preparation
- Increased harmonisation / best practices
- Increased clarity of regulatory expectations/ requirements



# In sight/ Joint Evaluation of paediatric and orphan legislations

#### - Background three studies



EVALUATION





### Thank you for your Attention

https://ec.europa.eu/health/human-use\_en